Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00143611 · ClinicalTrials.gov registry record · Phase 3

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

A Phase 3 study, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
277
Enrollment target

NCT00143611 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 277 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00143611, a Phase 3 study, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
277 participants
Enrollment target

Study Summary

The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.

Interventions

  • DRUG Placebo
  • DRUG Resatorvid

Trial Details

FieldValue
Enrollment Target 277 participants
Start Date 2005-09
Est. Completion 2007-02
Phase Phase 3

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT00143611

The ClinicalTrials.gov registry entry for NCT00143611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00143611 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00143611 about?

NCT00143611 is a clinical study titled "Efficacy & Safety of Resatorvid in Adults With Severe Sepsis". The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.

What is the current status of trial NCT00143611?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 277 participants. The study started on 2005-09. Estimated completion is 2007-02.

What interventions are being tested in trial NCT00143611?

The interventions under investigation include: Placebo (DRUG), Resatorvid (DRUG).

Who is sponsoring clinical trial NCT00143611?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.